ERBB2 and breast carcinoma: It is also unfortunate that none HSP90 inhibitors fulfilled all requirements to become an FDA-approved therapy to treat ErbB2-positive breast cancer so far, partly owing to the adverse side effects associated with the inhibition of HSP90 that maintains the stability and functionality of a wide range of client proteins [18].